½ÃÀ庸°í¼­
»óǰÄÚµå
1600717

Áø´Ü¿ë ½ÉÀü°è ½ÃÀå : Á¦Ç° À¯Çü, ¸®µå À¯Çü ¹× ÃÖÁ¾ »ç¿ëÀÚº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Diagnostic Electrocardiograph Market by Product (Devices, Software & Services), Lead Type (12-lead, 3-lead, 5-lead), End User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 192 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Áø´Ü¿ë ½ÉÀü°è ½ÃÀåÀº 2023³â¿¡ 112¾ï ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2024³â¿¡´Â 119¾ï 5,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 6.67%·Î ¼ºÀåÀ» Áö¼ÓÇÏ¿© 2030³â¿¡´Â 176¾ï 1,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù.

Áø´Ü¿ë ½ÉÀüµµ(ECG) ½ÃÀåÀº ½ÉÀåÀÇ Àü±âÀû Ȱµ¿À» ºñħ½ÀÀûÀ¸·Î ±â·ÏÇÏ¿© ½ÉÀå »óŸ¦ Áø´ÜÇÏ´Â Áß¿äÇÑ ±â´ÉÀ» Áß½ÉÀ¸·Î ¹ßÀüÇϰí ÀÖ½À´Ï´Ù. ÀÌ ±â¼úÀº ºÎÁ¤¸Æ, ½ÉÀ帶ºñ µî ´Ù¾çÇÑ ½ÉÀå °ü·Ã ÁúȯÀ» Á¶±â¿¡ ¹ß°ßÇÏ°í °ü¸®ÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇϸç, ECG´Â º´¿ø, Ŭ¸®´Ð, ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC), ÀçÅÃÄ¡·á µî ´Ù¾çÇÑ ÀÇ·á ÇöÀå¿¡¼­ Áø´Ü ¹× ¸ð´ÏÅ͸µ¿¡ ÇÊ¿äÇÑ ´Ù¾çÇÑ ¿ëµµ·Î Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù. ½ÃÀå ¼ºÀåÀº ½ÉÇ÷°ü ÁúȯÀÇ À¯º´·ü Áõ°¡, ¹«¼± ÈÞ´ë¿ë ½ÉÀüµµ Àåºñ¿Í °°Àº ±â¼ú ¹ßÀü, ¿¹¹æÀû °Ç°­°ü¸® ´ëÃ¥¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ Å©°Ô ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¤È®ÇÑ Áø´Ü°ú ¿¹Ãø ºÐ¼®À» Á¦°øÇÒ ¼ö ÀÖ´Â AI ÅëÇÕ ½ÉÀüµµ ½Ã½ºÅÛ °³¹ß¿¡µµ Å« ±âȸ°¡ ³ªÅ¸³ª°í ÀÖ½À´Ï´Ù. ¿ø°Ý ÀÇ·áÀÇ ¹ßÀü°ú ÇÔ²² ¿ø°Ý ¸ð´ÏÅ͸µ ¼Ö·ç¼ÇÀÇ µµÀÔµµ ½ÃÀå Á¡À¯À² È®´ë¿¡ µµ¿òÀÌ µÉ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ±×·¯³ª ÀÌ ½ÃÀåÀº °í±Þ ½ÉÀüµµ ÀåºñÀÇ ³ôÀº ºñ¿ë, »óȯ ¹®Á¦, º¹ÀâÇÑ Áø´Ü ½Ã½ºÅÛÀ» ¿î¿µÇÒ ¼ö ÀÖ´Â ¼÷·ÃµÈ ÀηÂÀÇ Çʿ伺 µîÀÇ ÇѰ迡 Á÷¸éÇØ ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ±ÔÁ¦ À庮°ú ±âÁ¸ ºê·£µå¿Í ½Å±Ô ½ÃÀå ÁøÃâ±â¾÷ °£ÀÇ °æÀï ¾Ð·Â µîÀÇ ¹®Á¦µµ ÀÖ½À´Ï´Ù. ±â¼ú Çõ½ÅÀÇ ±âȸ´Â dzºÎÇϸç, ƯÈ÷ ±â±âÀÇ ¿¬°á¼º, Á¤È®¼º, »ç¿ë ÆíÀǼº, ÀüÀÚ ÀÇ·á ±â·Ï°úÀÇ ÅëÇÕ µî ´Ù¾çÇÑ Çõ½Å ±âȸ°¡ ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¸Ó½Å·¯´×À» ÅëÇØ ECG ½ÅÈ£ÀÇ ÇØ¼®À» °³¼±Çϰí Áø´Ü Á¤È®µµ¸¦ Çâ»ó½ÃŰ´Â µ¥ ÁßÁ¡À» µÑ ¼ö ÀÖ½À´Ï´Ù. ±â¼ú ¹ßÀü°ú ÀÇ·áºñ Áõ°¡·Î ÀÎÇØ °æÀï ±¸µµÀº È®´ëµÇ´Â Ãß¼¼ÀÌÁö¸¸, ½ÃÀå »óȲÀº °æÀïÀûÀÓÀ» ½Ã»çÇÕ´Ï´Ù. ±â¾÷ÀÌ ¼ºÀåÇϱâ À§Çؼ­´Â ÀÌ·¯ÇÑ Ãß¼¼¿¡ ¸ÂÃß¾î ±â¼ú °øÀ¯¸¦ À§ÇÑ ÆÄÆ®³Ê½ÊÀ» ±¸ÃàÇϰí, ±ÔÁ¦ »óȲÀ» È¿À²ÀûÀ¸·Î ±Øº¹Çϰí, ȯÀÚ Á᫐ ¸ðµ¨¿¡ ÀûÀÀÇÒ ¼ö ÀÖ´Â À¯¿¬¼ºÀ» Ű¿ö¾ß ÇÕ´Ï´Ù. ±³À° ¼ö¿ä¿¡ ´ëÀÀÇÏ°í ºñ¿ë È¿À²ÀûÀÎ ¼Ö·ç¼ÇÀ» °³¹ßÇÏ´Â °Íµµ Àü·«ÀûÀ¸·Î ÇʼöÀûÀÔ´Ï´Ù. Àü¹ÝÀûÀ¸·Î, Áø´Ü¿ë ½ÉÀüµµ ½ÃÀåÀº °íÀ¯ÇÑ °úÁ¦¸¦ ÇØ°áÇϱâ À§ÇÑ Àü·«Àû Ž»öÀÌ ¿ä±¸µÇ´Â ¿ªµ¿ÀûÀÎ ½ÃÀåÀ̸ç, Çõ½ÅÀÇ ÀáÀç·ÂÀÌ Ç³ºÎÇÑ ¿ªµ¿ÀûÀΠȯ°æÀ» Á¦°øÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ(2023³â) 112¾ï ´Þ·¯
¿¹Ãø ¿¬µµ(2024³â) 119¾ï 5,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2030³â) 176¾ï 1,000¸¸ ´Þ·¯
CAGR(%) 6.67%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â Áø´Ü¿ë ½ÉÀü°è ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

Áø´Ü¿ë ½ÉÀü°è ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤, Àü·«Àû ÀÇ»ç°áÁ¤, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ¿ÏÈ­Çϰí, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • »ýȰ¾ç½ÄÀÇ ±Þ°ÝÇÑ º¯È­·Î ÀÎÇÑ Àü ¼¼°è ½ÉÇ÷°ü Áúȯ Áõ°¡
    • Àü ¼¼°è °í·ÉÈ­ Àα¸ ±ÞÁõ°ú ½ÉÇ÷°ü Áúȯ Á¶±â Áø´ÜÀÇ Çʿ伺
    • ¿þ¾î·¯ºí ¹× ¹«¼± ¿ø°Ý ¸ð´ÏÅ͸µ ±â±âÀÇ °³¹ß ¹× äÅà Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ºÒ¸®ÇÑ »óȯ Á¤Ã¥ ¹®Á¦
  • ½ÃÀå ±âȸ
    • º¸°ÇÀÇ·á ÀÎÇÁ¶ó°¡ Àß °®ÃçÁø ½ÅÈï °æÁ¦±¹µé ¼ö¿ä Áõ°¡
    • ÅõÀÚ Áõ°¡¿¡ µû¸¥ Áø´Ü ±â¼úÀÇ Áö¼ÓÀûÀÎ ¹ßÀü
  • ½ÃÀå °úÁ¦
    • °í±Þ ECG¸¦ Á¶ÀÛÇÏ´Â ¼÷·ÃµÈ Àü¹®°¡ ºÎÁ·

Portre's Five Forces: Áø´Ü¿ë ½ÉÀü°è ½ÃÀå Ž»öÀ» À§ÇÑ Àü·« µµ±¸

Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂû·ÂÀ» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : Áø´Ü¿ë ½ÉÀü°è ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ·Â ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº Áø´Ü¿ë ½ÉÀü°è ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® Áø´Ü¿ë ½ÉÀü°è ½ÃÀå¿¡¼­°æÀï ±¸µµ ÆÄ¾Ç

Áø´Ü¿ë ½ÉÀü°è ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­ ¹× ÅëÇÕ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÅëÂû·ÂÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º Áø´Ü¿ë ½ÉÀü°è ½ÃÀå¿¡¼­ÀÇ º¥´õ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â Áø´Ü¿ë ½ÉÀü°è ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀº º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ±¸ºÐÇÏ¿© »ç¿ëÀÚ°¡ Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù. ½Äº°ÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â Á¾ÇÕÀûÀÎ ½ÃÀå ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ¾÷°è ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅ͸¦ Æ÷ÇÔÇÑ ÇöÀç ½ÃÀå ȯ°æ¿¡ ´ëÇÑ »ó¼¼ÇÑ °ËÅä.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå Áø´Ü¿ë ½ÉÀü°è ½ÃÀå : Á¦Ç°º°

  • µð¹ÙÀ̽º
    • À̺¥Æ® ¸ð´ÏÅÍ
    • ȦÅÍ ¸ð´ÏÅÍ
    • ¸Å¸³Çü ·çÇÁ ¸®ÄÚ´õ
    • ¸ð¹ÙÀÏ ½ÉÀå ¿ø°Ý ÃøÁ¤ Àåºñ
    • ¾ÈÁ¤½Ã ½ÉÀüµµ Àåºñ
    • ½º¸¶Æ® ECG ¸ð´ÏÅÍ
    • ½ºÆ®·¹½º ½ÉÀüµµ Àåºñ
  • ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º

Á¦7Àå Áø´Ü¿ë ½ÉÀü°è ½ÃÀå : ¸®µå À¯Çüº°

  • 12 ¸®µå
  • 3 ¸®µå
  • 5 ¸®µå
  • 6 ¸®µå
  • ½Ì±Û ¸®µå

Á¦8Àå Áø´Ü¿ë ½ÉÀü°è ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
  • Áø´Ü¼¾ÅÍ
  • º´¿ø ¹× Ŭ¸®´Ð

Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ Áø´Ü¿ë ½ÉÀü°è ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Áø´Ü¿ë ½ÉÀü°è ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦11Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Áø´Ü¿ë ½ÉÀü°è ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦12Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023³â
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®

±â¾÷ ¸®½ºÆ®

  • Vectracor, Inc.
  • Suzuken Co., Ltd.
  • Aspel SA
  • Zimmer MedizinSysteme GmbH
  • Viatom Technology Co., Ltd.
  • Innomed Medical Zrt.
  • AliveCor, Inc.
  • Schiller AG
  • ACS Diagnostics
  • Koninklijke Philips N.V.
  • BPL Medical Technologies Pvt. Ltd.
  • ATsens Co., Ltd.
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • Bionet Co., Inc.
  • Edan Instruments, Inc.
  • Auxo Medical LLC
  • VYAIRE Medical, Inc.
  • Hill-Rom, Inc.
  • CompuMed, Inc.
  • BTL
  • Davis Medical Electronics, Inc.
  • Fukuda Denshi Co., Ltd.
  • Cardioline S.p.A.
  • Ambu A/S
  • OSI Systems, Inc.
  • Nihon Kohden Corporation
  • Norav Medical Ltd.
  • Custo Med GmbH
  • Lepu Medical Technology(Beijing) Co.,Ltd.
  • GE HealthCare Technologies Inc.
  • Shenzhen Comen Medical Instruments Co., Ltd.
LSH

The Diagnostic Electrocardiograph Market was valued at USD 11.20 billion in 2023, expected to reach USD 11.95 billion in 2024, and is projected to grow at a CAGR of 6.67%, to USD 17.61 billion by 2030.

The scope of the diagnostic electrocardiograph (ECG) market revolves around the essential function of diagnosing cardiac conditions through the non-invasive recording of electrical activity of the heart. This technology is pivotal in the early identification and management of numerous heart-related disorders, such as arrhythmias, heart attacks, and other conditions. The application of ECG extends across hospitals, clinics, ambulatory surgical centers, and home care, with the end-use scope involving both diagnostic and monitoring needs across various healthcare settings. Market growth is predominantly influenced by the increasing prevalence of cardiovascular diseases, advancements in technology such as wireless and portable ECG devices, and heightened awareness towards preventative healthcare measures. Additionally, significant opportunities are manifesting in the development of AI-integrated ECG systems that can provide accurate diagnostics and predictive analytics. Embracing remote monitoring solutions amid the rising trend of telemedicine is also promising for capturing market share. However, the market faces limitations such as the high cost of advanced ECG devices, reimbursement issues, and the need for trained personnel to operate complex diagnostic systems. Additional challenges include regulatory hurdles and competitive pressure among established brands and new entrants. Innovation opportunities abound, notably in enhancing device connectivity, precision, user-friendliness, and integration with electronic health records. Furthermore, research may focus on improving ECG signal interpretation through machine learning to enhance diagnostic accuracy. Market insights suggest a competitive but expanding landscape driven by technological evolution and increased healthcare expenditure. For growth, businesses should align with these trends, fostering partnerships for technology sharing, navigating regulatory landscapes efficiently, and fostering flexibility to adapt to patient-centric models. Addressing training needs and developing cost-effective solutions can also serve as strategic imperatives. Overall, the market for diagnostic ECGs presents a dynamic scene rich with innovation potential, albeit one that demands strategic navigation to address inherent challenges.

KEY MARKET STATISTICS
Base Year [2023] USD 11.20 billion
Estimated Year [2024] USD 11.95 billion
Forecast Year [2030] USD 17.61 billion
CAGR (%) 6.67%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Diagnostic Electrocardiograph Market

The Diagnostic Electrocardiograph Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rapidly Changing Lifestyles Increase the Incidence of Cardiovascular Diseases Worldwide
    • Surge in Global Aging Population and Need for Early Diagnosis of Cardiovascular Conditions
    • Increasing Development and Adoption of Wearable and Wireless Remote Monitoring Devices
  • Market Restraints
    • Issues with Unfavourable Reimbursement Policies
  • Market Opportunities
    • Emerging Demand from the Developing Economies with Improving Healthcare Infrastructure
    • Ongoing Advancements in Diagnostics with Increased Investments
  • Market Challenges
    • Lack of Skilled Expertise to Operate Advanced ECGs

Porter's Five Forces: A Strategic Tool for Navigating the Diagnostic Electrocardiograph Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Diagnostic Electrocardiograph Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Diagnostic Electrocardiograph Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Diagnostic Electrocardiograph Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Diagnostic Electrocardiograph Market

A detailed market share analysis in the Diagnostic Electrocardiograph Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Diagnostic Electrocardiograph Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Diagnostic Electrocardiograph Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Diagnostic Electrocardiograph Market, highlighting leading vendors and their innovative profiles. These include Vectracor, Inc., Suzuken Co., Ltd., Aspel SA, Zimmer MedizinSysteme GmbH, Viatom Technology Co., Ltd., Innomed Medical Zrt., AliveCor, Inc., Schiller AG, ACS Diagnostics, Koninklijke Philips N.V., BPL Medical Technologies Pvt. Ltd., ATsens Co., Ltd., Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Bionet Co., Inc., Edan Instruments, Inc., Auxo Medical LLC, VYAIRE Medical, Inc., Hill-Rom, Inc., CompuMed, Inc., BTL, Davis Medical Electronics, Inc., Fukuda Denshi Co., Ltd., Cardioline S.p.A., Ambu A/S, OSI Systems, Inc., Nihon Kohden Corporation, Norav Medical Ltd., Custo Med GmbH, Lepu Medical Technology(Beijing)Co.,Ltd., GE HealthCare Technologies Inc., and Shenzhen Comen Medical Instruments Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Diagnostic Electrocardiograph Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Devices and Software & Services. The Devices is further studied across Event Monitors, Holter Monitors, Implantable Loop Recorders, Mobile Cardiac Telemetry Devices, Resting ECG Devices, Smart ECG Monitors, and Stress ECG Devices.
  • Based on Lead Type, market is studied across 12-lead, 3-lead, 5-lead, 6-lead, and Single-lead.
  • Based on End User, market is studied across Ambulatory Surgical Centers, Diagnostic Centers, and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rapidly Changing Lifestyles Increase the Incidence of Cardiovascular Diseases Worldwide
      • 5.1.1.2. Surge in Global Aging Population and Need for Early Diagnosis of Cardiovascular Conditions
      • 5.1.1.3. Increasing Development and Adoption of Wearable and Wireless Remote Monitoring Devices
    • 5.1.2. Restraints
      • 5.1.2.1. Issues with Unfavourable Reimbursement Policies
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging Demand from the Developing Economies with Improving Healthcare Infrastructure
      • 5.1.3.2. Ongoing Advancements in Diagnostics with Increased Investments
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of Skilled Expertise to Operate Advanced ECGs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Growing utilization of software & services or data analysis and accurate interpretation
    • 5.2.2. Lead Type: Growing preference for 12-lead electrocardiograph as it provides the most detailed diagnostics
    • 5.2.3. End-User: Increasing potential of diagnostic electrocardiographs across hospitals & clinics with increased intensive care units and cardiac units
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. Diagnostic Electrocardiograph Market, by Product

  • 6.1. Introduction
  • 6.2. Devices
    • 6.2.1. Event Monitors
    • 6.2.2. Holter Monitors
    • 6.2.3. Implantable Loop Recorders
    • 6.2.4. Mobile Cardiac Telemetry Devices
    • 6.2.5. Resting ECG Devices
    • 6.2.6. Smart ECG Monitors
    • 6.2.7. Stress ECG Devices
  • 6.3. Software & Services

7. Diagnostic Electrocardiograph Market, by Lead Type

  • 7.1. Introduction
  • 7.2. 12-lead
  • 7.3. 3-lead
  • 7.4. 5-lead
  • 7.5. 6-lead
  • 7.6. Single-lead

8. Diagnostic Electrocardiograph Market, by End User

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
  • 8.3. Diagnostic Centers
  • 8.4. Hospitals & Clinics

9. Americas Diagnostic Electrocardiograph Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Diagnostic Electrocardiograph Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Diagnostic Electrocardiograph Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Acorai Wins EUR 2.3 Million Grant to Help Fund Trial for Heart Monitoring Device
    • 12.3.2. AliveCor Collaborates with European Remote Patient Monitoring Company, Offering its 'Virtual Heart Clinic in a Box'
    • 12.3.3. UltraLinQ to Launch New Cardiac Monitoring Product at Arab Health

Companies Mentioned

  • 1. Vectracor, Inc.
  • 2. Suzuken Co., Ltd.
  • 3. Aspel SA
  • 4. Zimmer MedizinSysteme GmbH
  • 5. Viatom Technology Co., Ltd.
  • 6. Innomed Medical Zrt.
  • 7. AliveCor, Inc.
  • 8. Schiller AG
  • 9. ACS Diagnostics
  • 10. Koninklijke Philips N.V.
  • 11. BPL Medical Technologies Pvt. Ltd.
  • 12. ATsens Co., Ltd.
  • 13. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • 14. Bionet Co., Inc.
  • 15. Edan Instruments, Inc.
  • 16. Auxo Medical LLC
  • 17. VYAIRE Medical, Inc.
  • 18. Hill-Rom, Inc.
  • 19. CompuMed, Inc.
  • 20. BTL
  • 21. Davis Medical Electronics, Inc.
  • 22. Fukuda Denshi Co., Ltd.
  • 23. Cardioline S.p.A.
  • 24. Ambu A/S
  • 25. OSI Systems, Inc.
  • 26. Nihon Kohden Corporation
  • 27. Norav Medical Ltd.
  • 28. Custo Med GmbH
  • 29. Lepu Medical Technology(Beijing)Co.,Ltd.
  • 30. GE HealthCare Technologies Inc.
  • 31. Shenzhen Comen Medical Instruments Co., Ltd.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦